calcimedica inc glp-1 receptor agonists weight management diabetes treatments GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review Patient education tips for GLP-1,

In addition, SGLT-2is contribute to better cardiovascular outcomes by stimulating erythropoiesis (leading to improved oxygenation of ischemic tissues), reducing proinflammatory adipokines, and reducing cardiac necrosis [16, 53,54,55,56]

That's why Novo Nordisk sees it as only the beginning of a much bigger, longer-term assault on obesity

Findings from a phase 2 study on petrelintide were presented today at an American Diabetes Association (ADA) conference

[DOI] [PMC free article] [PubMed] [Google Scholar] 700.Barrera J.G., Jones K.R., Herman J.P., D'Alessio D.A., Woods S.C., Seeley R.J

For something you can actually get today, semaglutide and tirzepatide are the approved options

But a follow-up 2021 study, known as STEP 4, showed that within 48 weeks of no longer taking semaglutide, participants regained approximately two-thirds of their prior weight loss, while those who remained on GLP-1 drug therapy continued to lose weight